BioNTechs, Cash

BioNTech's Cash Pile Meets Its Legal Bills as Founders Weigh a Transfer of Rights

Published on 11/16/2026 at 03:02 | Editorial boerse-global.de
BioNTech lifted its 2026 revenue midpoint to €1.7–1.9B, agreed to buy an FDA priority review voucher for $205M, and faces expanding patent claims.
BioNTech's Cash Pile Meets Its Legal Bills as Founders Weigh a Transfer of Rights Illustration mit AI erstellt.

BioNTech investors are juggling three storylines at once: a raised revenue target, a costly push into oncology, and a widening legal fight over its COVID-19 vaccine technology. Add to that a fresh round of media chatter about the company's founders and what they might take with them when they go.

Talks are reportedly underway over whether rights held by BioNTech could be contributed to the founders' new venture, according to media reports dated November 3. The coverage described a possible contribution of rights — not an agreed transfer.

A profitable quarter, a loss-making year so far

The company's third-quarter 2026 results, already published, showed revenue of €1.29 billion and an IFRS net profit of €184.5 million. A year earlier, quarterly revenue had come in at €1.52 billion. Management pinned the decline chiefly on weaker demand for COVID-19 vaccines.

Adjusted diluted earnings per share fell to €1.76 from €3.11 in the prior-year quarter. Over the first nine months of 2026, BioNTech recorded an IFRS net loss of €1.17 billion on revenue of €1.51 billion.

Guidance raised, spending plans untouched

Even so, the company lifted the midpoint of its 2026 revenue forecast, putting the expected range at €1.7 billion to €1.9 billion. The outlook for adjusted research, development, selling and administrative costs was left as it was. Cash, cash equivalents and securities investments totaled €16.2 billion, according to company figures.

Should investors sell immediately? Or is it worth buying BioNTech?

The higher top-line target therefore does not rest on growth in the revenue actually booked during the quarter.

$205 million for a faster review

On the oncology side, BioNTech has agreed to buy an FDA Priority Review Voucher from Scholar Rock for $205 million in cash. The company intends to use the voucher to support a future marketing application for a candidate from its late-stage oncology pipeline. The transaction is subject to customary closing conditions, including HSR clearance.

Media reports noted that BioNTech has not disclosed which oncology candidate will use the voucher. The purchase itself has yet to close.

Patent battles spread

Legal pressure is mounting in parallel. Arbutus and Genevant have disclosed a change to their Canadian action against Pfizer and BioNTech, seeking damages and injunctions tied to mRNA-LNP COVID-19 vaccines. Newly announced Japanese claims, meanwhile, target Pfizer Japan.

Media reports on Friday linked renewed investor interest in BioNTech to the expanded patent dispute. They also pointed to a completed share buyback as a counterweight to the burdens of the litigation.

Analysts trim targets, keep their ratings

Views on the stock remain mixed. Robert Burns of HC Wainwright cut his price target to $110 from $130 last Monday while keeping his buy recommendation, according to media reports — a lower target paired with an unchanged rating.

Ad

BioNTech Stock: New Analysis - 16 November

Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated BioNTech analysis...

Disclaimer...
en | US09075V1026 | BIONTECHS | boerse | 70518667 |